Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Iron in Severe Heart Failure Without Iron Deficiency
NCT03042130Phase 4Withdrawn
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Dec 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose in heart failure (HF) (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Functioning improvement and Quality of life improvement. Planned start Dec 2016; status: withdrawn.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03042130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042130.